Dyslipidemia, statins and prostate cancer.

about

Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

P2860

Q54982147-1B4D568D-C368-44C7-BB31-B6C4D5932CD4

P2860

Dyslipidemia, statins and prostate cancer.

Item

http://www.wikidata.org/entity/Q38030598

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dyslipidemia, statins and prostate cancer.

@en

type

Item

label

Dyslipidemia, statins and prostate cancer.

@en

prefLabel

Dyslipidemia, statins and prostate cancer.

@en

P1476

Dyslipidemia, statins and prostate cancer.

@en

P2093

Kevin R Rice

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Michael O Koch

http://www.w3.org/2001/XMLSchema#string

Timothy A Masterson

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells.

Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.

Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.

Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

P304

981-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.75

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22845413

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

Dyslipidemia, statins and prostate cancer.

about

P2860

P2860

Dyslipidemia, statins and prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921